Aurobindo Pharma arm's biosimilar gets marketing nod from U.K.'s MHRA
In February 2025, Zefylti had received the marketing authorisation in the European Union from the European Commission (EC). This is CuraTeQ's second biosimilar to be approved by MHRA. Bevqolva was the first in December 2024, Aurobindo Pharma said in a filing on Tuesday.
In December, announcing receipt of positive opinion for Zefylti from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA), the company had said the product is intended for the treatment of neutropenia and the mobilisation of peripheral progenitor cells (PBPCs).
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Mint
16 hours ago
- Mint
Aurobindo Pharma shares tumble almost 5% on reports of Zentiva acquisition bid; company issues clarification
Aurobindo Pharma shares declined nearly 5 percent to ₹ 1,039 apiece on August 20 after reports suggested that the company had emerged as the frontrunner to acquire Prague-based generic drugmaker Zentiva from Advent International. The potential deal, valued at $5-5.5 billion ( ₹ 43,500-47,900 crore), would mark the largest-ever acquisition by an Indian pharmaceutical company, both within India and overseas. If concluded, the transaction would surpass previous landmark pharma deals, including Daiichi Sankyo's $3.2 billion acquisition of Ranbaxy in 2014 and Biocon Biologics' $3.3 billion cash-and-stock purchase of the global biosimilars business of US-based Viatris. Reports highlighted that the Zentiva buyout could strengthen Aurobindo's footprint in Europe, particularly in Eastern European markets such as the Czech Republic, Romania, and Slovakia—regions considered promising growth areas for biosimilars as patent expiries of major prescription drugs accelerate. Responding to the reports, the Pharma company issued a statement under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company said it routinely explores strategic opportunities, including acquisitions and partnerships, to enhance shareholder value. However, it stressed that no binding agreement or definitive decision had been approved by the board in relation to the reported transaction. Aurobindo added that the news should be treated as premature and not be relied upon. It assured that any definitive development requiring disclosure would be promptly communicated to the stock exchanges in line with regulatory requirements. On the financial front, Aurobindo Pharma posted a consolidated net profit of ₹ 824 crore in the June 2025 quarter (Q1 FY26), a decline of 10.2 percent year-on-year compared with ₹ 918 crore in Q1 FY25. Revenue from operations, however, grew four percent to ₹ 7,868 crore from ₹ 7,567 crore a year earlier. Operating EBITDA stood at ₹ 1,603 crore in Q1 FY26, marginally lower than ₹ 1,619.6 crore in Q1 FY25. EBITDA margin contracted to 20.4 percent from 21.4 percent in the year-ago period. Regionally, US formulations revenue fell 1.9 percent year-on-year to ₹ 3,488 crore ($408 million), impacted by destocking and seasonal headwinds. Meanwhile, European formulations revenue registered robust growth of 18 percent year-on-year to ₹ 2,338 crore. The stock hit an intraday low of ₹ 1,039.30, marking a 4.7 percent decline. Over the last 12 months, Aurobindo Pharma's shares have shed more than 28 percent, with a year-to-date fall of 22 percent in 2025, reflecting persistent investor caution.
&w=3840&q=100)
Business Standard
17 hours ago
- Business Standard
Aurobindo Pharma leads $5 billion race to acquire Prague-based Zentiva
Aurobindo Pharma has emerged as the leading contender to buy Prague-based drugmaker Zentiva from private equity (PE) firm Advent International in a deal estimated at $5-5.5 billion, The Economic Times reported on Wednesday, citing sources. If the deal goes through, it would mark the biggest acquisition by an Indian pharmaceutical company globally. Another firm in the fray includes the United States (US)-based private equity firm GTCR, the report added. 'No binding agreement' yet: Aurobindo However, soon after the report surfaced, Aurobindo issued a clarification stating that "no binding agreement or definitive decision" has been made yet regarding the deal. "The Company regularly explores various strategic opportunities in the ordinary course of its business, including potential acquisitions and partnerships, to enhance long-term shareholder value. However, at present, no binding agreement or definitive decision has been made by the board of directors of the company in relation to the transaction referred to in the said article(s). Accordingly, the said news item is premature and should not be relied upon," the company said in a BSE filing. European push The deal could further expand Aurobindo's presence in the European market, where the firm is already performing well. In the first quarter of the financial year 2025-26 (Q1 FY26), it reported an 18 per cent year-on-year (Y-o-Y) revenue growth in European markets, which stood at ₹2,338 crore, driven by a strong performance across all key segments. Similarly, revenue from growth markets formulations increased by 8.8 per cent Y-o-Y to ₹772 crore in the June quarter, compared to ₹709 crore in the same period last year. Overall, Aurobindo Pharma reported a 10.2 per cent Y-o-Y drop in consolidated profit after tax (PAT) for Q1 FY26, which stood at ₹824 crore. The decline was attributed to a drop in sales in its active pharmaceutical ingredients business and the US market. However, the drugmaker recorded a 4 per cent rise in revenue from operations, reaching ₹7,868 crore in the June quarter, up from ₹7,567 crore in Q1 FY25. Shares of Aurobindo Pharma fell almost 4 per cent to ₹1,047 apiece on the BSE at 2:14 pm following the report.
&w=3840&q=100)
Business Standard
4 days ago
- Business Standard
Aurobindo Pharma expects China plant to break even at Ebitda level in FY26
Aurobindo Pharma expects its China facility to break even in the third quarter of the current financial year, according to its CFO Santhanam Subramanian. The Hyderabad-based drug maker commenced operations at the facility in the last week of November 2024 and is now ramping up production. "This facility with an initial capacity of 2 billion units plus is ramping up as expected and will begin contributing to revenue in the coming quarters and is expected to break even at the Ebitda (earnings before interest, taxes, depreciation, and amortisation) level by Q3 FY26," Subramanian said in an analyst call. He noted that around $145 million has been invested in the facility, which commenced production and invoicing in Q4 FY25 and Q1 FY26, respectively. Elaborating on other investments, Subramanian said the company has invested about $70 million in two US facilities, with production expected to start in the current fiscal year. Elaborating further, he noted that the company plans to file for more than 20 products in the US and Europe from its Eugia-V plant in Visakhapatnam. He noted that the company has invested around $30 million in the Biologics CMO business so far, and the balance of $100 million plus capital is expected to be invested by March 2027. On business outlook, Subramanian stated: "Looking ahead, we remain optimistic about sustaining our growth momentum. Our confidence is supported by expected volume expansion, continued product launches and a stable pricing environment, especially in the US and Europe". Commercial operations ramping up at new manufacturing sites would further support the topline growth and margin improvement in the upcoming quarters, he added. "We are confident of achieving our internal target margin of 20-21 per cent in FY26," Subramanian stated. Aurobindo Pharma reported a 10 per cent year-on-year dip in its consolidated net profit to ₹824 crore for the June quarter, due to a fall in sales in the US and API business vertical. Its revenue from operations increased to ₹7,868 crore for the June quarter against ₹7,567 crore in the year-ago period.
